- The Company is engaged in 4 product lines of Pharmaceuticals are Vaccines, Biologicals, formulations, Natural Products.

- The Company has been promoted by Mr. Sosh, Kumar Jain, who is a pharmacist having about 40 years of experience in the pharmaceutical industry.

1993 - The name of the Company changed to Panacea Biotec Limited on 7th September.

- The Company now proposes to expand the capacity of Vaccines Division, along with an expansion in the capacities of capsules and suspensions.

1994 - The Company is using technology developed in-house and is not entering into any technical collaboration as it has adequate technical expertise.

1995 - During the year the company is public issue of 21,28,000 No. of Equity Shares of Rs. 10/- each for cash at a premiumof Rs. 50/- per share aggregating Rs. 1276/80 Lacs, and reservation of 6,72,000 No. of Equity Shares of Rs. 10/- each for cash at a premium of Rs. 50/- per share aggregating Rs. 4,03,20,000 for firm allotment to NRIs/OCB's.

1996 - The Company has successfully commissioned a state-of-the-art Viral Vaccine Research facility at Latru near Chandigarh.

1997 - Panacea Biotec (PBL) has been going global with a gusto. It has introduced some speciality formulations like Nimulid and, two of these are under worldwide patent in PBL's name with applications filed in 72 countries.

1999 - During the year under review, the Company had allotted 50,00,000 - 12% Redeemable Cumulative Preference Shares of Rs.10/- each aggregating Rs.5.00 Crores to Industrial Development Bank of India on private placement basis.

2000 - Panacea Biotech Ltd, a pharmaceutical company in North India, is exploring opportunities for growth through expansion, diversification and backward integration.

- The company has proposed an amendment in articles of association for implementing the depository system for its stocks.

- The company's various product introductions like Nimulid, Livoluc, Nimulid gel, Risipid etc have been well received in the market.

- Panacea Biotec Ltd (PBL) has entered into a joint venture with Heber Biotec Ltd (HBL) of Cuba to manufacture Hepatitis-B vaccine in bulk form. A new company - Pan Heber Biotec Ltd - has been formed for the purpose in which the two partners hold equal stake.

- The company is setting up another plant at Lalru to manufacture branded formulations for the export market.

- The company is planning to launch an anti-histamine drug in June this year.

- Panacea Biotech has set up two wholly-owned subsidiary companies in the UK and Hong Kong with the objective of importing and exporting pharmaceutical, technology and other products.

- The Company has entered into agreement with NSDL and CDSL for dematerialisation.

2001 - Panacea Biotec Ltd (PBL), a Delhi-based pharma company, has recently signed an agreement with National Research Development Corporation (NRDC) to commercialise the know-how for an opthalmic formulation of ocular delivery, using nanotechnology.

2002

-Appoints Mr Rajesh Jain and Mr Sandeep Jain as the Joint Managing Directors of the company.

-Files for worldwide patent for its new NDDS for an anti-TB combination drug.

-Board approves for the subdivision of shares from Rs.10 per share of Re.1 per share , and also decides to wind up the company's wholly owned subsidiary at Isle of Man, UK.

-Company's non-executive director makes a gift of 2,01,000 shares of Re.1 each representing 0.35% of the company's total capital.

-Commences marketing of herbal and dietary supplement products under its SBU viz. "Best on Health" and launches ThankGod capsules, ThankGod Anytime cream, ThankGod pain & Itch relief cream etc.

2003

-Stock split from Rs 10 per equity share to Rs 1 per equity share

- Panacea Biotec forays OTC market with Herbal Products

2004

-California-based Chiron Vaccines, the world's 5th largest vaccine producer, has struck a deal with Delhi-based Panacea Biotec to set up a joint venture in India

-Panacea Biotec launches new product HEARTFELT, natural therapy for cholesterol management developed by its Research & Development Team.

-Panacea rolls out new nimesulide injection

-Launches Combination vaccines through JV with Chiron Vaccines, UK on November 24, 2004

2005

-Panacea Biotec launches 'Upright' for effective relief from severe pain & inflammation

-Panacea Biotec introduces Noval Anti-allergy Drug - Ralif

2006

-Panacea Biotec enters into an agreement with PT Bio Farma to manufacture Measles Vaccine

2007

- Panacea Biotec signs agreement with Family Vaccines to supply combination vaccines

2009

- Panacea Biotec - EasyFive Injects; USD 222.37 million Award by UNICEF

2010

- Panacea Biotech's Baddi unit gets US FDA approval

- Panacea Bio - Board recommends Dividend of Re. 0.25 (25%) each on Equity Shares of the Company, for the financial year 2009-10.

2011

- PanaceBiotec - Panacea Biotec Launches - PacliALL

- Panacea Biotec announced that the company is mulling to foray into healthcare infrastructure sector with setting up of multi specialty hospital in Gurgaon, Haryana.

2012

- PanaceBiotec - Panacea Biotec celebrates 63rd Indian Republic day with launch of "POLPROTEC" in Nigeria".

- Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria

- PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit

- PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical

- Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines

2013 -Panacea Biotec Ltd has opened up its wholly owned subsidiary in UAE in the name of Panol Industries.

2014 -Panacea Biotec Ltd has entered into collaboration with a leading International Pharmaceutical Company for the development and supply of an immunosuppressant generic product in USA. - "Panacea Biotec Announces Collaboration with Rising Pharmaceuticals Inc.". -Company has received UNICEF Award for supply of Companys DTB-HebB-Hib (Pentavalent) Vaccine Easyfive-TT to UNICEF.

2015 -Panacea Biotec Gets Pan American Health Organization (PAHO) order for supply of EasyFive-TT Vaccines worth

2016 -"Panacea Biotec Launches - CABAPAN, A Cost Effective product for the treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC)". -Panacea Biotec Receives Prestigious Intellectual Property & Science Award "Top 50 Indian Innovators 2015"". -Panacea Biotec Launches - TENEPAN, a cost effective product for the treatment of Type 2 Diabetes Mellitus (T2DM)". -"Panacea Biotec Introduces World's First Fully Liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib".

2017 -Panacea Biotec Introduces World's First Fully Liquid Hexavalent Combination Vaccine EasySixTM for Six Preventable Diseases. -Panacea Biotec announces ANDA approval for US Market and LTA & Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT). -Panacea Biotec Announces Joint Collaboration with Bionpharma Inc.

2018 -Panacea Biotec inks Tripartite Agreement with Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc. for manufacturing and supply of Azacitidine injection in the U.S. Market.

2019 -Panacea Biotec Announces Launch Of ViLACT For Treatment Of Uncontrolled Type 2 Diabetes Mellitus Patients. -Panacea Biotec receives USD 24.32 Million Award of Pentavalent Vaccine from U.N. Agencies.

2021 -RDIF and Panacea Biotec launch the production of Sputnik V in India. -Panacea Biotec supplies 1st shipment of the second component of Sputnik V vaccine produced in India.

2022

-Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine.. -CEPI, THSTI and Panacea Biotec partner to develop broadly protective Betacoronavirus vaccines.

2023

-Panacea Biotec launches EasyFourPol in India and receives registration of Valganciclovir Powder for Oral Solution in Germany.

- Panacea Biotec Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a genericversion of Abraxane.

-Launch of new range of high-quality pediatric food & nutritional products in India by Company's wholly owned subsidiary, Panacea Biotec Pharma Limited '.